T2 Biosystems Recognizes Sepsis Awareness Month with Thought Leadership Campaign and Participation in Sepsis Alliance Health Equity Pledge
September 01 2021 - 5:59PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection
of sepsis-causing pathogens, today announced efforts in recognition
of Sepis Awareness Month to educate on the importance of rapid
diagnostic technologies at a time when sepsis is the most common
complication observed in severe cases of COVID-19.1,2
The ongoing COVID-19 pandemic has increased the risk for
infections, as patients who are hospitalized for COVID-19 are 22
percent more likely to develop sepsis and 113 percent more likely
to experience septic shock as compared to influenza
patients.3 COVID-19 patients with bloodstream
infections (BSIs) have significantly longer hospitalizations and a
higher rate of ICU admission and mortality compared to those
without BSIs.4 Given the need for education on this
matter, T2 Biosystems will highlight sepsis as a critical public
health issue throughout September via dedicated social media
content and collateral, conference sponsorships, tradeshow
presentations, and a continued partnership with Sepis Alliance to
support key initiatives like the Sepsis Alliance Summit and the
Equity, Diversity, and Inclusion Pledge.
“While sepsis continues to cause the death of millions of people
each year, it has more recently become a common complication for
those battling severe cases of COVID-19,” said John Sperzel,
Chairman and Chief Executive Offiicer of T2 Biosystems. "It's
widely-understood within the medical community that the early
detection of sepsis is critical in improving patient outcomes and
reducing the length of hospital stays. By partnering with prominent
industry organizations and raising the awareness on the importance
of culture-independent rapid diagnostics, like those offered by T2
Biosystems, we can help to save lives and improve outcomes."
Sepsis is the body’s immune response to infection and is
considered a medical emergency that requires rapid diagnosis and
treatment. It causes 11 million deaths worldwide5 each year,
contributing to 20 percent of all deaths globally and taking more
lives than cancer,6,7 and costs the U.S. healthcare system $62
billion annually.8 As part of its commitment to continuing this
important conversation, T2 Biosystems is involved in several
industry programs this September, including:
- Health Equity Pledge: Created by the Sepsis
Alliance – the leading sepsis organization in the U.S. – the
Equity, Diversity, and Inclusion Pledge is meant to foster health
equity and mitigate the global challenges associated with
antimicrobial resistance, sepsis and its underlying causes. T2
Biosystems joins other medical diagnostic, technology, and
pharmaceutical companies supporting the pledge to drive diverse
participation in clinical trials, better reach and educate diverse
communities about products, make products more accessible, and
increase diversity within its organization.
- Sepsis Alliance Summit: T2 Biosystems is the
presenting sponsor of the second annual Sepsis Alliance Summit, a
virtual summit hosted by Sepsis Alliance from September 14 – 16
that explores sepsis-related topics in healthcare. On Tuesday,
September 14 at 10:45 a.m. ET, John Sperzel, Chairman and Chief
Executive Officer of T2 Biosystems, will share his journey as a
heart transplant recipient and sepsis survivor and lead an opening
session titled “Rapid Diagnostics and the Impact on Sepsis”. At
11:30 a.m. ET, Aparna Ahuja, MD, Chief Medical Officer at T2
Biosystems, will lead the session, “Culture-Independent Testing: A
New Way to Hurdle Obstacles for Detection of Sepsis-Causing
Pathogens and Improve Patient Outcomes” and the Company will host a
virtual booth as part of the exhibition.
- AACC Annual Scientific Meeting and Clinical Lab
Expo: The American Association for Clinical Chemisty’s
annual meeting, taking place in Atlanta, GA between September 26 –
30, will showcase cutting-edge science and technology shaping the
future of laboratory medicine. On Tuesday, September 28 at 3:30
p.m. ET, T2 Biosystems will host a workshop titled, “It’s a New
Era: Culture-Independent Tests for Rapid Detection of
Sepsis-Causing Pathogens that Lead to Positive Healthcare
Outcomes.
- IDWeek: IDWeek is the joint annual meeting of
the Infectious Diseases Society of America (IDSA), Society for
Healthcare Epidemiology of America (SHEA), the HIV Medical
Association (HIVMA), the Pediatric Infectious Diseases Society
(PIDS), and the Society of Infectious Diseases Pharmacists (SIDP)
taking place virtually between September 29 and October 3. The
conference provides an opportunity to learn from industry experts
for the improvement of patient care and public health.
T2 Biosystems is committed to overcoming the challenges
associated with diagnosing and treating bloodstream infections and
sepsis, namely due to the lengthy time it currently takes to
receive blood culture results, which typically takes days. T2
Biosystems’ T2Bacteria® Panel and T2Candida® Panel are the first
and only FDA-cleared diagnostic tests to identify sepsis-causing
pathogens directly from whole blood. This enables rapid, targeted
therapy, which can help save lives and reduce hospital costs. Last
year, the Company also received Emergency Use
Authorization from the U.S. Food and Drug Administration (FDA)
for its COVID-19 molecular diagnostic test, the
T2SARS-CoV-2™ Panel. The Panel runs on the Company’s
FDA-cleared and fully-automated T2Dx® Instrument. To learn
more, visit www.t2biosystems.com.
About T2 BiosystemsT2 Biosystems, a leader in
the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and T2Lyme™
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Media Contact:Meagan Dominick, Vault
Communicationsmdominick@vaultcommunications.com 773-369-4255
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
________________________1 Zhou F, et al. Lancet. 2020; 395
(10229), 1054-1062.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext
2 Chen T, et al. BMJ. 2020; 368:m1091.
https://www.bmj.com/content/368/bmj.m1091 3 Little DR, et al. Epic
Health Research Network. 2020.
https://ehrn.org/articles/sepsis-and-mortality-rates-are-higher-in-patients-hospitalized-for-covid-19-than-for-influenza
4 Khatri A, et al., Open Forum Infect Dis, 2021.
https://doi.org/10.1093/ofid/ofab339 5 Sepsis, World Health
Organization. Accessed August 2021.
https://www.who.int/news-room/fact-sheets/detail/sepsis 6 Rudd KE,
et al. Lancet. 2020;395(10219):200-211.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32989-7/fulltext
7 Cancer, World Health Organization. Accessed August 2021.
https://www.who.int/health-topics/cancer#tab=tab_1 8 Buchman, T.G
et al. Crit Care Med. 2020 48(3):302-318.
https://journals.lww.com/ccmjournal/FullText/2020/03000/Sepsis_Among_Medicare_Beneficiaries__3__The.4.aspx
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024